Lite Strategy, Inc.

Lite Strategy, Inc. is a biopharmaceutical company engaged in pre-clinical development programs for non-oncologic disease indications, after historically developing cancer therapies. The company's drug candidate pipeline features voruciclib, an orally administered cyclin-dependent kinase 9 inhibitor, and zandelisib, an oral selective PI3Kδ inhibitor. In addition to pharmaceutical research, the company maintains Litecoin as a primary treasury reserve asset and manages covered call option strategies on its digital asset holdings. Potential customers and commercial partners include biotechnology and pharmaceutical companies, research institutions, and healthcare collaborators targeted for out-licensing, program sales, or clinical development partnerships.

Because the company is focused on early-stage drug candidate research and treasury management, it does not operate commercial retail stores, manufacturing facilities, or consumer service locations. Operational, regulatory, and patent activities are carried out primarily in the United States, alongside patent holdings across international jurisdictions. The provided text does not disclose the location of the company's corporate headquarters.

Summary of the business section of Lite Strategy's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of June 30, 2026, we had five employees whom all reside in the United States and were engaged in business development, finance, information systems or administrative support.”